Medicine and Dentistry
Partial Nephrectomy
100%
Prostate Cancer
92%
Neoplasm
90%
Robot-Assisted Prostatectomy
73%
Overall Survival
67%
Cystectomy
57%
Transitional Cell Carcinoma
57%
Continence
51%
Recurrence Free Survival
35%
Retroperitoneal Lymph Node Dissection
33%
Glomerular Filtration Rate
32%
Clear Cell Renal Cell Carcinoma
32%
Urinary System
30%
Retrospective Study
28%
Neoadjuvant Chemotherapy
28%
Enfortumab Vedotin
28%
Prostate Specific Antigen
27%
Disease
26%
Multivariate Analysis
24%
Bleeding
24%
Recurrent Disease
23%
Cancer Specific Survival
22%
Urine Incontinence
22%
Surgical Margin
21%
Magnetic Resonance Imaging
19%
Castration Resistant Prostate Cancer
17%
Bladder Cancer
17%
Bone Metastasis
17%
Propensity Score Matching
16%
Body Mass Index
16%
Adverse Event
16%
Prognostic Factor
16%
Urinary Diversion
16%
Postoperative Ileus
16%
Biochemical Recurrence
16%
Ischemia
16%
Progression Free Survival
15%
Biological Marker
15%
Kidney Tumour
15%
Nephroureterectomy
15%
Operation Duration
15%
Disease Exacerbation
15%
Urine Cytology
15%
Kidney Metastasis
15%
Prostate Adenocarcinoma
14%
Pembrolizumab
14%
Brachytherapy
14%
Long Term Survival
14%
Extracorporeal
14%
Iodine 125
14%
Combination Therapy
14%
Ileal Conduit
14%
Radical Nephrectomy
14%
Liposarcoma
14%
Olaparib
14%
Fournier Gangrene
14%
Ureter
14%
Bladder Metastasis
14%
Procollagen
14%
Corynebacterium urealyticum
14%
Surgeon
14%
Bronchogenic Cyst
14%
Alkaline Phosphatase
14%
Inferior Vena Cava
14%
Molecularly Targeted Therapy
14%
Cabazitaxel
14%
P16
14%
Muscle Invasive Bladder Cancer
14%
Thrombectomy
14%
Dentigerous Cyst
14%
Ligation
14%
Spermatic Cord
14%
Computer Assisted Tomography
14%
Oncology
14%
Immunoglobulin
14%
Function Test
14%
Oral Function
14%
Physical Examination
14%
Inguinal Orchiectomy
14%
Acid Phosphatase Prostate Isoenzyme
11%
Kidney Function
11%
Clinical Trial
10%
Ileus
10%
Cabozantinib
10%
Diagnosis
9%
Geriatrics
8%
Bone Scintigraphy
8%
Targeted Therapy
8%
Metastatic Carcinoma
7%
Columnar Epithelium
7%
Lenabasum
7%
Alcohol Abstinence
7%
Nutritional Status Assessment
7%
Pyeloplasty
7%
Tongue
7%
Predictive Factor
6%
Diseases
6%
Pelvis
6%
Prostatectomy
6%
Lymphovascular Invasion
6%
Keyphrases
Prostate Cancer
28%
Poor Prognosis
15%
Robot-assisted Radical Prostatectomy
14%
Pentafecta Outcomes
14%
Nerve Sparing
14%
High-grade Urothelial Carcinoma
14%
Partial Nephrectomy
14%
Prospective multi-institutional Study
14%
Renal Hilar Tumor
14%
Bladder Metastasis
14%
C-X-C Chemokine Receptor Type 4 (CXCR4)
14%
Deep Ensemble
14%
Robot-assisted Radical Nephrectomy
14%
Prostate-specific Antigen Response
14%
Ensemble Machine Learning
14%
Inferior Vena Cava Thrombectomy
14%
Testicular Epidermoid Cyst
14%
Alkaline Phosphatase
14%
Type I Procollagen
14%
Urethral Suspension
14%
Selective Clamping
14%
Regulatory T Cells
14%
Spermatic Cord
14%
Computed Tomography
14%
Premature Termination Codon
14%
Bladder Eversion
14%
Real-world Application
14%
Infiltration
14%
High-grade Prostate Cancer
14%
Secondary Bladder Cancer
14%
Liposarcoma
14%
Voided Urine Cytology
14%
Nuclear Area
14%
Efficacy Comparison
14%
Cancer Tissue
14%
Fournier's Gangrene
14%
Encrusted Pyelitis
14%
Abdominal MRI
14%
Corynebacterium Urealyticum
14%
Pseudostratified
14%
Bronchogenic Cyst
14%
Columnar Epithelium
14%
Disease Impact
14%
Retroperitoneal Mass
14%
Retroperitoneal Bronchogenic Cyst
14%
Carboxyl Terminus
14%
Abdominal US
14%
Intracorporeal Ileal Conduit
14%
Bone Metastasis
14%
Stripping Technique
14%
Resistance to Immunotherapy
14%
Intraoperative Navigation
14%
High Complexity
14%
Laparoscopic Retroperitoneal Lymph Node Dissection
14%
Propeptide
14%
Prostate Cancer Outcomes
14%
Outcome Patterns
14%
Prognostic Stratification
14%
125I Seed Implantation
14%
Alanine-serine-cysteine Transporter
14%
Immuno-oncology
14%
AR-V7
14%
Androgen Receptor Splice Variant
14%
Clear Cell Renal Cell Carcinoma (ccRCC)
14%
Prognostic Factors
14%
Clinical Outcomes
14%
Combination Therapy
14%
Function Test
14%
Blood Test Results
14%
Oral Function
14%
Extended Follow-up
14%
Single-center Study
14%
Antimicrobial Activity
14%
Acute Cystitis
14%
Escherichia Coli
14%
Treg
13%
Hormonal Agents
12%
Prostate-specific Antigen
11%
Prostatic Acid Phosphatase
11%
Bladder Neck Reconstruction
10%
Primary Resistance
9%
Prostate-specific Antigen Failure
9%
Oral Diadochokinesis
9%
Third-generation Cephalosporins
9%
Inguinal Orchiectomy
9%
Estimated Glomerular Filtration Rate
9%
Geriatric 8
8%
Bone Scan
8%
Inhibitor Combination
7%
Retroperitoneal Lymph Node Dissection (RPLND)
7%
Teratoma with Malignant Transformation
7%
Testicular Mass
7%
Continence Recovery
7%
Biologically Effective Dose
7%
Rectus Fascia
7%
Cystopexy
7%
22Rv1
7%
Burch Colposuspension
7%
Time off
7%
Abstinence from Alcohol
7%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
66%
Kidney Metastasis
57%
Renal Cell Carcinoma
57%
Prostate Cancer
44%
Castration Resistant Prostate Cancer
42%
Immunotherapy
31%
Combination Therapy
29%
Neoplasm
28%
Cabazitaxel
28%
Immunoglobulin
28%
Immune Checkpoint Inhibitor
24%
Biological Marker
22%
Prostate Specific Antigen
22%
Cancer Specific Survival
20%
Progression Free Survival
19%
Disease
18%
Malignant Neoplasm
18%
Adverse Event
18%
Docetaxel
17%
C Reactive Protein
17%
Androgen Receptor
16%
Disease Exacerbation
16%
Pembrolizumab
14%
Chemotherapy
14%
Bladder Cancer
14%
Recurrence Risk
14%
Heat Shock Protein 27
14%
Racemase
14%
Biochemical Recurrence
14%
Brain Disease
14%
Tryptophan 2,3 Dioxygenase
14%
Metastatic Colorectal Cancer
14%
Muscle Invasive Bladder Cancer
14%
Olaparib
14%
Transitional Cell Carcinoma
14%
Enfortumab Vedotin
14%
Acid Phosphatase Prostate Isoenzyme
11%
Indoleamine 2,3 Dioxygenase
10%
Axitinib
10%
Cabozantinib
10%
Survival Rate
10%
Branched Chain Amino Acid
9%
Recurrent Disease
9%
Protein Tyrosine Kinase Inhibitor
7%
Kynurenine
6%
Recurrence Free Survival
5%
Liver Metastasis
5%